Home  /  Resource Library  /  Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Real world study investigating first line treatment selection in cll.